<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>


Investor Relations

Welcome to Trovagene Investor Relations

Corporate Profile

Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  

Company Overview - May 2017
June 7, 2017
11:30am - 12:00pm PDT

Trovagene CEO, Bill Welch, will be presenting at the 7th Annual LD Micro Invitational Conference June 7, 2017 at 11:30 AM PDT at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. The...

email print
Stock Information
Contact Investor Relations

Direct     [USA +1] 858-952-7593

E-mail    ir@trovagene.com